Serina Therapeutics Inc (SER) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $2.24 (+0.90%), Market cap $0.03B, 52-week low–high $1.28 ~ $6.18.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 20
Financial statements, price targets, institutional (13F) holdings and related news for Serina Therapeutics Inc are updated in real time on BlackAll Trade.
Serina Therapeutics Inc trades at $2.24 (+0.90%). Real-time quotes and charts are available on BlackAll Trade.
Serina Therapeutics Inc has a market cap of about $0.03B.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment o